The most impactful findings on AML from the European Hematology Association 2026 Congress are highlighted in this research ...
Treatment with risvutatug rezetecan improves survival in relapsed small cell lung cancer compared with topotecan, researchers ...
According to the researchers, there are limited effective treatment options for relapsed SCLC after first-line immunotherapy ...
The addition of local consolidation therapy to ipilimumab plus nivolumab numerically shortens survival in stage IV non-small ...
In this extended follow-up from the phase 3 KEYNOTE-826 trial, researchers reported on 5-year outcomes of pembrolizumab and chemotherapy in cervical cancer.
Ambient air pollution promotes tumorigenesis and is associated with poor OS for Canadian patients, particularly nonsmokers.
First-line treatment with amivantamab plus lazertinib maintains clinically meaningful and durable antitumor efficacy in ...
Perioperative atezolizumab plus chemotherapy failed to meet its primary endpoint of independent review facility event-free ...
Adding amivantamab to first-line chemotherapy improves OS in patients with advanced NSCLC who have EGFR exon 20 insertion ...
Adjuvant osimertinib can improve overall survival in patients with EGFR-mutated, early-stage non-small-cell lung cancer ...
The addition of zipalertinib to platinum-based chemotherapy was associated with a statistically significant and clinically ...
Researchers aimed to determine how spending for prostate cancer-related health care changed from 2012 to 2021, and which components of care accounted for these changes.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results